Provided by Tiger Fintech (Singapore) Pte. Ltd.

Senti Biosciences, Inc.

3.49
+0.28008.72%
Post-market: 3.46-0.0300-0.86%19:28 EDT
Volume:90.78K
Turnover:312.78K
Market Cap:16.85M
PE:-0.22
High:3.88
Open:3.18
Low:3.10
Close:3.21
Loading ...

Company Profile

Company Name:
Senti Biosciences, Inc.
Exchange:
NASDAQ
Establishment Date:
2016
Employees:
48
Office Location:
2 Corporate Drive,First Floor,South San Francisco,California,United States
Zip Code:
94080
Fax:
- -
Introduction:
Senti Biosciences, Inc. operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma. It also develops SENTI-401, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer/CRC cells. In addition, the company develops Tumor-Associated Antigen and Protective Antigen Paired Discovery Platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells. The company has a strategic collaboration with Celest Therapeutics (Shanghai) Co. Ltd for the clinical development of SENTI-301A to treat solid tumors. Senti Biosciences, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

Directors

Name
Position
Timothy Lu
Chief Executive Officer, President and Director
Brenda Cooperstone
Director
David Epstein
Director
Edward Mathers
Director
James Collins
Director
Omid Farokhzad
Director
Susan Berland
Director

Shareholders

Name
Position
Timothy Lu
Chief Executive Officer, President and Director
Deborah Knobelman
Chief Financial Officer, Treasurer and Head of Corporate Development
Kanya Rajangam
Head of Research and Development and Chief Medical Officer
Philip Lee
Chief Technology Officer and Corporate Secretary